Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA] - N0000193802

Pharmacologic Class Information

Pharmacologic Code N0000193802
Pharmacologic Name Interleukin 5 Receptor alpha-directed Antibody Interactions
Pharmacologic Uses
  • interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa)
Pharmacologic Concept Mechanisms of Action - [MoA]
Pharmacologic Concept Description This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with Interleukin 5 Receptor alpha-directed Antibody Interactions

The following table contains 2 products whose active ingredient are classified under the same pharmacologic class Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
0310-1730Fasenra Non-Proprietary Name: BenralizumabInjection, SolutionSubcutaneousAstrazeneca Pharmaceuticals LpACTIVE
0310-1830Fasenra Non-Proprietary Name: BenralizumabInjection, SolutionSubcutaneousAstrazeneca Pharmaceuticals LpACTIVE